We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 81

FTC v. Phoebe Putney Health System, Inc., et al.
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 20 2013

On February 19, 2013, the United States Supreme Court in Federal Trade Commission v. Phoebe Putney Health System, Inc., et al., unanimously rejected


Anti-assignment provisions and providers
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • August 6 2015

Beginning last year, there has been a rash of court decisions giving ERISA participant andor beneficiary status to providers based on assignments


FTC v. St. Luke's Health System, Ltd.: Ninth Circuit holds that acquisition of physician group practice violates antitrust laws, requires divestiture
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 11 2015

On February 10, 2015, the Ninth Circuit affirmed a district court ruling in favor of the Federal Trade Commission that the acquisition of an Idaho


U.S. Supreme Court refines & limits antitrust state action defense
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 26 2015

On February 25, 2015, the United States Supreme Court issued a 6-3 opinion in North Carolina State Bd of Dental Examiners v. FTC, which held that a


Dueling court cases issued on same day
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • July 24 2014

On Tuesday morning the U.S. Court of Appeals for the District of Columbia Circuit ruled that an IRS rule for a key piece of the 2010 Affordable Care


Disability claims procedures get an Affordable Care Act makeover
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • November 18 2015

In light of the volume of litigation involving claims for disability benefits, and the perceived need to improve procedural protections for workers


Amgen v Apotex - 180-Day Advance Notice of Biosimilar Marketing is Mandatory
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • December 11 2015

The Federal Circuit in July said in its Amgen-Sandoz decision that declining to share information under the biosimilars pathway "patent dance" made


Myriad questions with but two answers: isolated DNA is patentable subject matter but certain diagnostic method claims are patent
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • July 29 2011

In reversing the summary judgment of the Southern District of New York, the Court of Appeals for the Federal Circuit held today in an opinion by Judge Lourie that claims to isolated DNA and claims for methods of screening potential cancer therapeutics were directed to patentable subject matter


NLRB sets a heightened standard for employers challenging narrow bargaining units
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • September 21 2011

When a union petitions the National Labor Relations Board to be certified as the bargaining representative for a group of employees, it identifies the group or "bargaining unit" that it seeks to represent


TTAB rules that fraud in less than all classes does not warrant cancellation of multi-class registration in toto
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • February 11 2009

On January 29, 2009, the Trademark Trial and Appeal Board (“TTAB”) of the United States Patent and Trademark Office answered a significant open question in the post-Medinol era, namely, whether a finding of fraud with regard to fewer than all International Classes in a multi-Class trademark registration requires cancellation of the entire registration or whether cancellation will be limited to all goodsservices in the Class in which fraud is found